Flurbiprofen suppresses the inflammation, proliferation, invasion and migration of colorectal cancer cells via COX2

Wang,Xiaobo; Ye,Xuxing; Zhang,Yili; Ji,Feng

doi:10.3892/ol.2020.11993

Flurbiprofen suppresses the inflammation, proliferation, invasion and migration of colorectal cancer cells via COX2

Authors:
- Xiaobo Wang
- Xuxing Ye
- Yili Zhang
- Feng Ji
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China, Traditional Medicine Center, Jinhua Hospital, Zhejiang University, Jinhua, Zhejiang 321000, P.R. China, Physical Examination Center, Jinhua Hospital, Zhejiang University, Jinhua, Zhejiang 321000, P.R. China
Published online on: August 20, 2020 https://doi.org/10.3892/ol.2020.11993
Article Number: 132
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer is an aggressive disease with a poor prognosis and low survival rate at the advanced stage, therefore new innovative targets are urgently required. Flurbiprofen has been reported to exhibit therapeutic effects in other types of cancer, such as esophageal cancer, breast cancer and colorectal cancer. Therefore, the present study aimed to investigate the function of flurbiprofen in colorectal cancer. SW620 colorectal cancer cells were treated with different concentrations of flurbiprofen to determine the optimum concentration. Subsequently, COX2 expression affected by flurbiprofen was tested using western blotting, reverse transcription‑quantitative PCR and immunofluorescence. Enzyme‑linked immunosorbent assay was used to determine the levels of tumor necrosis factor‑α, interleukin (IL)‑6 and IL‑1β. Cell Counting Kit‑8, colony formation and flow cytometry assays were used to assess the proliferation and apoptosis of SW620 cells in various groups. Western blotting was performed to investigate the expression of proliferation‑, apoptosis‑ and migration‑related proteins after different treatments. Wound healing and Transwell assays were performed to measure the invasion and migration of colorectal cancer cells, respectively. The results demonstrated that flurbiprofen inhibited colorectal cancer cell proliferation. Furthermore, it was identified that flurbiprofen inhibited the expression of COX2. Notably, flurbiprofen suppressed the expression of inflammatory factors by inhibiting COX2. Moreover, flurbiprofen inhibited the proliferation, invasion and migration of colorectal cancer cells by inhibiting COX2. In conclusion, the present study revealed that flurbiprofen inhibited COX2 expression in colorectal cancer, and affected the proliferation, invasion, migration and apoptosis of colorectal cancer cells. These results expand the understanding of the function of COX2 in colorectal cancer and the effect of flurbiprofen on COX2 expression.

View Figures

View References

1	Cho YA, Lee J, Oh JH, Chang HJ, Sohn DK, Shin A and Kim J: Inflammatory dietary pattern, IL-17F genetic variant, and the risk of colorectal cancer. Nutrients. 10:7242018. View Article : Google Scholar
2	Xue J, Ge X, Zhao W, Xue L, Dai C, Lin F and Peng W: PIPKIγ regulates CCL2 expression in colorectal cancer by activating AKT-STAT3 signaling. J Immunol Res. 2019:36905612019. View Article : Google Scholar : PubMed/NCBI
3	Xu M, Chen X, Lin K, Zeng K, Liu X, Pan B, Xu X, Xu T, Hu X, Sun L, et al: The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p. Mol Cancer. 17:1412018. View Article : Google Scholar : PubMed/NCBI
4	Lal N, White BS, Goussous G, Pickles OJ, Mason M, Beggs AD, Taniere P, Willcox BE, Guinney J and Middleton G: KRAS mutation and consensus molecular subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer. Clin Cancer Res. 24:224–233. 2018. View Article : Google Scholar : PubMed/NCBI
5	Liang Q, Ma D, Zhu X, Wang Z, Sun TT, Shen C, Yan T, Tian X, Yu T, Guo F, et al: RING-finger protein 6 amplification activates JAK/STAT3 pathway by modifying SHP-1 ubiquitylation and associates with poor outcome in colorectal cancer. Clin Cancer Res. 24:1473–1485. 2018. View Article : Google Scholar : PubMed/NCBI
6	Hannigan GD, Duhaime MB, Ruffin MT, Koumpouras CC and Schloss PD: Diagnostic potential and interactive dynamics of the colorectal cancer Virome. MBio. 9:e2248–e2218. 2018. View Article : Google Scholar
7	Ricker CN, Hanna DL, Peng C, Nguyen NT, Stern MC, Schmit SL, Idos GE, Patel R, Tsai S, Ramirez V, et al: DNA mismatch repair deficiency and hereditary syndromes in latino patients with colorectal cancer. Cancer. 123:3732–3743. 2017. View Article : Google Scholar : PubMed/NCBI
8	Riley JM, Cross AW, Paulos CM, Rubinstein MP, Wrangle J and Camp ER: The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. Cancer. 124:1650–1659. 2018. View Article : Google Scholar : PubMed/NCBI
9	Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC and Giordano SH: Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. J Geriatr Oncol. 10:705–708. 2019. View Article : Google Scholar : PubMed/NCBI
10	Subramanian S, Hoover S, Tangka FKL, DeGroff A, Soloe CS, Arena LC, Schlueter DF, Joseph DA and Wong FL: A conceptual framework and metrics for evaluating multicomponent interventions to increase colorectal cancer screening within an organized screening program. Cancer. 124:4154–4162. 2018. View Article : Google Scholar : PubMed/NCBI
11	Zhang L, Shu R, Zhao Q, Li Y, Yu Y and Wang G: Preoperative butorphanol and flurbiprofen axetil therapy attenuates remifentanil-induced hyperalgesia after laparoscopic gynaecological surgery: A randomized double-blind controlled trial. Br J Anaesth. 117:504–511. 2016. View Article : Google Scholar : PubMed/NCBI
12	Wobst I, Ebert L, Birod K, Wegner MS, Hoffmann M, Thomas D, Angioni C, Parnham MJ, Steinhilber D, Tegeder I, et al: R-flurbiprofen traps prostaglandins within cells by inhibition of multidrug resistance-associated protein-4. Int J Mol Sci. 18:682016. View Article : Google Scholar
13	Wang Y, Zhang HB, Xia B, Wang GM and Zhang MY: Preemptive analgesic effects of flurbiprofen axetil in patients undergoing radical resection of esophageal carcinoma via the left thoracic approach. Chin Med J (Engl). 125:579–582. 2012.PubMed/NCBI
14	Ashraf Z, Alamgeer, Kanwal M, Hassan M, Abdullah S, Waheed M, Ahsan H and Kim SJ: Flurbiprofen-antioxidant mutual prodrugs as safer nonsteroidal anti-inflammatory drugs: Synthesis, pharmacological investigation, and computational molecular modeling. Drug Des Devel Ther. 10:2401–2419. 2016. View Article : Google Scholar : PubMed/NCBI
15	Zhou Y, Huang J, Bai Y, Li C and Lu X: Effects of preemptive analgesia with flurbiprofen ester on lymphocytes and natural killer cells in patients undergoing esophagectomy: A randomized controlled pilot study. Thorac Cancer. 8:649–654. 2017. View Article : Google Scholar : PubMed/NCBI
16	Wang D, Yang XL, Chai XQ, Shu SH, Zhang XL, Xie YH, Wei X, Wu YJ and Wei W: A short-term increase of the postoperative naturally circulating dendritic cells subsets in flurbiprofen-treated patients with esophageal carcinoma undergoing thoracic surgery. Oncotarget. 7:18705–18712. 2016. View Article : Google Scholar : PubMed/NCBI
17	Otsuka N, Yataba I, Matsushita I, Matsumoto H, Hoshino Y and Terada Y: A minimal impact of long-term S-flurbiprofen plaster application on kidney function in osteoarthritis patients. Clin Exp Nephrol. 21:1060–1067. 2017. View Article : Google Scholar : PubMed/NCBI
18	Yin Y, Yi Y, Yu J, Sun X, Liu C and Xu F: Effects of flurbiprofen on serum level of interleukin-6, prostacyclin and corticosteroid A2 in patients with bone metastases of cancer. Oncol Lett. 15:1545–1548. 2018.PubMed/NCBI
19	Ooki A, Del Carmen Rodriguez Pena M, Marchionni L, Dinalankara W, Begum A, Hahn NM, VandenBussche CJ, Rasheed ZA, Mao S, Netto GJ, et al: YAP1 and COX2 coordinately regulate urothelial cancer stem-like cells. Cancer Res. 78:168–181. 2018. View Article : Google Scholar : PubMed/NCBI
20	Aich A, Wang C, Chowdhury A, Ronsör C, Pacheu-Grau D, Richter-Dennerlein R, Dennerlein S and Rehling P: COX16 promotes COX2 metallation and assembly during respiratory complex IV biogenesis. Elife. 7:e325722018. View Article : Google Scholar : PubMed/NCBI
21	Basudhar D, Glynn SA, Greer M, Somasundaram V, No JH, Scheiblin DA, Garrido P, Heinz WF, Ryan AE, Weiss JM, et al: Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer. Proc Natl Acad Sci USA. 114:13030–13035. 2017. View Article : Google Scholar : PubMed/NCBI
22	Sun Y, Dai H, Chen S, Zhang Y, Wu T, Cao X, Zhao G, Xu A, Wang J and Wu L: Disruption of chromosomal architecture of cox2 locus sensitizes lung cancer cells to radiotherapy. Mol Ther. 26:2456–2465. 2018. View Article : Google Scholar : PubMed/NCBI
23	Jiang WW, Wang QH, Peng P, Liao YJ, Duan HX, Xu M, Li Y and Zhang PB: Effects of flurbiprofen axetil on postoperative serum IL-2 and IL-6 levels in patients with colorectal cancer. Genet Mol Res. 14:16469–16475. 2015. View Article : Google Scholar : PubMed/NCBI
24	Wirrig EE, Gomez MV, Hinton RB and Yutzey KE: COX2 inhibition reduces aortic valve calcification in vivo. Arterioscler Thromb Vasc Biol. 35:938–947. 2015. View Article : Google Scholar : PubMed/NCBI
25	Yu J, Jiang L, Gao Y, Sun Q, Liu B, Hu Y and Han X: Interaction between BMSCs and EPCs promotes IUA angiogenesis via modulating PI3K/Akt/Cox2 axis. Am J Transl Res. 10:4280–4289. 2018.PubMed/NCBI
26	Lee CW, Lin ZC, Hu SC, Chiang YC, Hsu LF, Lin YC, Lee IT, Tsai MH and Fang JY: Urban particulate matter down-regulates filaggrin via COX2 expression/PGE2 production leading to skin barrier dysfunction. Sci Rep. 6:279952016. View Article : Google Scholar : PubMed/NCBI
27	Ooki A, Begum A, Marchionni L, VandenBussche CJ, Mao S, Max K and Hoque MO: Arsenic promotes the COX2/PGE2-SOX2 axis to increase the malignant stemness properties of urothelial cells. Int J Cancer. 143:113–126. 2018. View Article : Google Scholar : PubMed/NCBI
28	Marutha Muthu AK, Cheah PL, Koh CC, Chew MF, Toh YF and Looi LM: Cyclooxygenase-2 (COX2) expression in adenocarcinoma surpasses that of squamous cell carcinoma in the uterine cervix. Malays J Pathol. 39:251–255. 2017.PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
30	Kim SR, Park JH, Lee ME, Park JS, Park SC and Han JA: Selective COX-2 inhibitors modulate cellular senescence in human dermal fibroblasts in a catalytic activity-independent manner. Mech Ageing Dev. 129:706–713. 2008. View Article : Google Scholar : PubMed/NCBI
31	MacDowell KS, Marsá MD, Buenache E, Villatoro JML, Moreno B, Leza JC and Carrasco JL: Inflammatory and antioxidant pathway dysfunction in borderline personality disorder. Psychiatry Res. 284:1127822020. View Article : Google Scholar : PubMed/NCBI
32	Xiao J, Wang F, Lu H, Xu S, Zou L, Tian Q, Fu Y, Lin X, Liu L, Yuan P, et al: Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells. Cell Death Dis. 10:7772019. View Article : Google Scholar : PubMed/NCBI
33	Shan ZG, Sun ZW, Zhao LQ, Gou Q, Chen ZF, Zhang JY, Chen W, Su CY, You N, Zhuang Y and Zhao YL: Up-regulation of TINAGL1 promotes gastric cancer growth and metastasis by regulating multiple MMPs expression. J Gastroenterol Hepatol. Jun 14–2020.(Epub ahead of print). doi: 10.1111/jgh.15150. View Article : Google Scholar
34	Ji L, Chen S, Gu L and Zhang X: Exploration of potential roles of m6A regulators in colorectal cancer prognosis. Front Oncol. 10:7682020. View Article : Google Scholar : PubMed/NCBI
35	Shu X, Xiang YB, Rothman N, Yu D, Li HL, Yang G, Cai H, Ma X, Lan Q, Gao YT, et al: Prospective study of blood metabolites associated with colorectal cancer risk. Int J Cancer. 143:527–534. 2018. View Article : Google Scholar : PubMed/NCBI
36	Mojica CM, Glenn BA, Chang C and Bastani R: The relationship between neighborhood immigrant composition, limited english proficiency, and late-stage colorectal cancer diagnosis in california. Biomed Res Int. 2015:4601812015. View Article : Google Scholar : PubMed/NCBI
37	Butt J, Blot WJ, Teras LR, Visvanathan K, Le Marchand L, Haiman CA, Chen Y, Bao Y, Sesso HD, Wassertheil-Smoller S, et al: Antibody responses to streptococcus gallolyticus subspecies gallolyticus proteins in a large prospective colorectal cancer cohort consortium. Cancer Epidemiol Biomarkers Prev. 27:1186–1194. 2018. View Article : Google Scholar : PubMed/NCBI
38	Li H, Zhou J, Wei X, Chen R, Geng J, Zheng R, Chai J, Li F and Jiang S: miR-144 and targets, c-fos and cyclooxygenase-2 (COX2), modulate synthesis of PGE2 in the amnion during pregnancy and labor. Sci Rep. 6:279142016. View Article : Google Scholar : PubMed/NCBI
39	Shiow LR, Favrais G, Schirmer L, Schang AL, Cipriani S, Andres C, Wright JN, Nobuta H, Fleiss B, Gressens P and Rowitch DH: Reactive astrocyte COX2-PGE2 production inhibits oligodendrocyte maturation in neonatal white matter injury. Glia. 65:2024–2037. 2017. View Article : Google Scholar : PubMed/NCBI
40	Amrite AC and Kompella UB: Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism. J Pharmacol Exp Ther. 324:749–758. 2008. View Article : Google Scholar : PubMed/NCBI
41	Duncan K, Uwimpuhwe H, Czibere A, Sarkar D, Libermann TA, Fisher PB and Zerbini LF: NSAIDs induce apoptosis in nonproliferating ovarian cancer cells and inhibit tumor growth in vivo. IUBMB Life. 64:636–643. 2012. View Article : Google Scholar : PubMed/NCBI
42	Hu JC, Chai XQ, Wang D, Shu SH, Magnussen CG, Xie LX and Hu SS: Intraoperative flurbiprofen treatment alters immune checkpoint expression in patients undergoing elective thoracoscopic resection of lung cancer. Med Princ Pract. 29:150–159. 2020. View Article : Google Scholar : PubMed/NCBI